Linezolid
Active ingredient: Linezolid
In short: Linezolid is indicated for the treatment of nosocomial pneumoniacaused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae . Linezolid is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, including cases
What is Linezolid used for?
Linezolid is indicated for the treatment of nosocomial pneumoniacaused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae .
Linezolid is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) .
Linezolidis indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae. Linezolid has not been studied in the treatment of decubitus ulcers .
Linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes .
Linezolid is indicated for the treatment of vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia .
•Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected .
•The safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials . …
Linezolid dosage
The recommended dosage for linezolid formulations for the treatment of infections is described in Table 1.
InfectionDue to the designated pathogens . | Dosage, Route, and Frequency of Administration | Recommended Durationof Treatment(Consecutive Days)
Pediatric Patients
Neonates less than 7 days: Most pre-term neonates less than 7 days of age (gestational age less than 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg every 8 hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg every 8 hours by 7 days of life .
(Birth through 11 Years of Age) | Adults and Adolescents (12 Years and Older)
Nosocomial pneumonia | 10 mg/kgintravenously or oralOral dosing using either linezolid tablets or Linezolid for Oral Suspension .
every 8 hours | 600 mgintravenously or oral
every 12 hours | 10 to 14
Community-acquired pneumonia, including concurrent bacteremia
Complicated skin and skin structure infections
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia | 10 mg/kgintravenously or oral
every 8 hours | 600 mgintravenously or oral
every 12 hours | 14 to 28
Uncomplicated skin and skin structure infections | less than 5 yrs:10 mg/kg oral
every 8 hours
5 to 11 yrs:10 mg/kg oral
every 12 hours | Adults:400 mg oral
every 12 hours
Adolescents:600 mg oral
every 12 hours | 10 to 14
No dose adjustment is necessary when switching from intravenous to oral administration.
Linezolid for Oral Suspension is supplied as a powder for constitution. Gently tap bottle to loosen powder. Add a total of 123 mL distilled water in two portions. After adding the first half, shake vigorously to wet all of the powder. Then add the second half of the water and shake vigorously to obtain a uniform suspension. After constitution, each 5 mL of the suspension contains 100 mg of linezolid. Before using, gently mix by inverting the bottle 3 to 5 times. Do not shake. Store constituted suspension at room temperature. Use within 21 days after constitution.
How to take Linezolid — instructions & advice from the label
Important Administration Instructions
Advise patients that linezolid may be taken with or without food.
Peripheral and Optic Neuropathy
Advise patients to inform their physician if they experience changes in vision while taking linezolid .
Serotonin Syndrome
Advise patients to inform their physician if taking serotonergic agents, including serotonin reuptake inhibitors or other antidepressants and opioids. Advise patients of the increased risk of serotonin syndrome when Linezolid is used concomitantly with serotonergic agents .
Potential Interactions Producing Elevation of Blood Pressure
•Advise patients to inform their physician if they have a history of hypertension.
•Advise patients to avoid large quantities of foods or beverages with high tyramine content while taking
linezolid. Foods high in tyramine content include those that may have undergone protein changes by aging, fermentation, pickling, or smoking to improve flavor, such as aged cheeses, fermented or air-dried meats, sauerkraut, soy sauce, tap beers, and red wines. The tyramine content of any protein-rich food may be increased if stored for long periods or improperly refrigerated. …
Warnings & precautions
Do not take this medicine if: Linezolid formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components.
Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Thrombocytopenia has been reported more often in patients with severe renal impairment, whether or not on dialysis, and in patients with moderate to severe hepatic impairment. Complete blood counts should be monitored weekly in patients who receive linezolid, particularly in those who receive linezolid for longer than two weeks, those with pre-existing myelosuppression, those with severe renal impairment or moderate to severe hepatic impairment, those receiving concomitant drugs that produce bone marrow suppression, or those with a chronic infection who have received previous or concomitant antibacterial drug therapy. Discontinuation of therapy with linezolid should be considered in patients who develop or have worsening myelosuppression .
Peripheral and optic neuropathies have been reported in patients treated with linezolid, primarily in those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with linezolid for less than 28 days. …
Linezolid side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The safety of linezolid formulations was evaluated in 2,046 adult patients enrolled in seven Phase 3 comparator-controlled clinical trials, who were treated for up to 28 days.
Of the patients treated for uncomplicated skin and skin structure infections (uSSSIs), 25.4% of linezolid-treated and 19.6% of comparator-treated patients experienced at least one drug-related adverse event. For all other indications, 20.4% of linezolid-treated and 14.3% of comparator-treated patients experienced at least one drug-related adverse event.
Table 2 shows the incidence of all-causality, treatment-emergent adverse reactions reported in at least 1% of adult patients in these trials by dose of linezolid.
Uncomplicated Skin and Skin Structure Infections | All Other Indications
ADVERSE REACTIONS | Linezolid400 mg by mouthevery 12 hours(n=548) | Clarithromycin250 mg by mouthevery 12 hours(n=537) | Linezolid600 mg every 12 hours(n=1498) | All Other ComparatorsComparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours. …
Drug interactions
Linezolid is a reversible, nonselective inhibitor of monoamine oxidase .
Linezolid has the potential for interaction with adrenergic and serotonergic agents .
About this medicine
Linezolid for Oral Suspension contains linezolid, which is a synthetic antibacterial agent of the oxazolidinone class. The chemical name for linezolid is N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-ox- azolidinyl]methyl] acetamide.
The molecular formula is C16H20FN3O4. Its molecular weight is 337.35, and its chemical structure is represented below:
Linezolid for Oral Suspension is supplied as an orange-flavored powder for constitution into a suspension for oral administration. Following constitution, each 5 mL contains 100 mg of linezolid. Inactive ingredients are aspartame, carboxymethylcellulose sodium, citric acid (anhydrous), colloidal silicon dioxide, hypromellose, mannitol, microcrystalline cellulose, natural orange flavor, sodium benzoate, sodium chloride, sodium citrate, sucrose, and xanthan gum . The sodium (Na+) content is 8.52 mg per 5 mL (0.4 mEq per 5 mL).
How it works: Linezolid is an antibacterial drug . …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 16007ca5-7956-4414-af38-406a6623400e. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin